TY - JOUR
T1 - Association of NCF1 polymorphism with systemic lupus erythematosus and systemic sclerosis but not with ANCA-associated vasculitis in a Japanese population
AU - Yokoyama, Nozomi
AU - Kawasaki, Aya
AU - Matsushita, Takashi
AU - Furukawa, Hiroshi
AU - Kondo, Yuya
AU - Hirano, Fumio
AU - Sada, Kenei
AU - Matsumoto, Isao
AU - Kusaoi, Makio
AU - Amano, Hirofumi
AU - Nagaoka, Shouhei
AU - Setoguchi, Keigo
AU - Nagai, Tatsuo
AU - Shimada, Kota
AU - Sugii, Shoji
AU - Hashimoto, Atsushi
AU - Matsui, Toshihiro
AU - Okamoto, Akira
AU - Chiba, Noriyuki
AU - Suematsu, Eiichi
AU - Ohno, Shigeru
AU - Katayama, Masao
AU - Migita, Kiyoshi
AU - Kono, Hajime
AU - Hasegawa, Minoru
AU - Kobayashi, Shigeto
AU - Yamada, Hidehiro
AU - Nagasaka, Kenji
AU - Sugihara, Takahiko
AU - Yamagata, Kunihiro
AU - Ozaki, Shoichi
AU - Tamura, Naoto
AU - Takasaki, Yoshinari
AU - Hashimoto, Hiroshi
AU - Makino, Hirofumi
AU - Arimura, Yoshihiro
AU - Harigai, Masayoshi
AU - Sato, Shinichi
AU - Sumida, Takayuki
AU - Tohma, Shigeto
AU - Takehara, Kazuhiko
AU - Tsuchiya, Naoyuki
N1 - Funding Information:
Dr. Hirano is employed by The Department of Lifetime Clinical Immunology of Tokyo Medical and Dental University (TMDU), which has received unrestricted research grants from Chugai Pharmaceutical Co., Ltd.; Ono Pharmaceuticals; Mitsubishi Tanabe Pharma Co.; UCB Japan; CSL Behring; Towa Pharmaceutical Co., Ltd.; Abbvie Japan Co., Ltd.; Japan Blood Products Organization; Ayumi Pharmaceutical Co.; and Nippon Kayaku Co., Ltd., with which TMDU currently pays the salary of Dr. Hirano. Dr. Hirano has also received speaking fees from Ono Pharmaceuticals, Astellas Pharma Inc., Sumitomo Dainippon Pharma and Chugai Pharmaceutical Co., Ltd. Dr. Shimada has received lecture fee from Chugai. Dr. Furukawa has the following conflicts, and the following funders are supported wholly or in part by the indicated pharmaceutical companies. The Japan Research Foundation for Clinical Pharmacology is run by Daiichi Sankyo, the Takeda Science Foundation is supported by an endowment from Takeda Pharmaceutical Company and the Nakatomi Foundation was established by Hisamitsu Pharmaceutical Co., Inc. The Daiwa Securities Health Foundation was established by Daiwa Securities Group Inc. and Mitsui Sumitomo Insurance Welfare Foundation was established by Mitsui Sumitomo Insurance Co., Ltd. Dr. Furukawa was also supported by research grants from Bristol-Myers Squibb Co., and received honoraria from Ajinomoto Co., Inc., Daiichi Sankyo Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., Pfizer Japan Inc., and Takeda Pharmaceutical Company, Luminex Japan Corporation Ltd., and Ayumi Pharmaceutical Corporation. Dr. Tohma was supported by research grants from Abbott Japan Co., Ltd., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Merck Sharp and Dohme Inc., Pfizer Japan Inc., Takeda Pharmaceutical Company Limited and Teijin Pharma Limited. Dr. Sugihara has received honoraria from Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co. Ltd., Mitsubishi-Tanabe Pharma Co., Astellas Pharma Inc., Bristol Myers Squibb K.K., Pfizer Japan Inc., UCB Japan Co. Ltd., and Abbvie Japan Co., Ltd., and has received research grant support from Takeda Pharmaceutical Co., Ltd, Astellas Pharma Inc., and Teijin Pharma Ltd. Dr. A. Hashimoto has received research funding from Chugai Pharmaceutical Co., Ltd. Dr. Matsui has received research funding from Chugai Pharmaceutical Co., Ltd. and Janssen Pharmaceutical K K. Dr. Tamura has received research grant from Ayumi Pharmaceutical Co., Asahi Kasei. Pharma Co., Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co. Ltd., Mitsubishi-Tanabe Pharma Co., Astellas Pharma Inc., Bristol Myers Squibb K.K., Abbvie Japan Co., Ltd., and Eisai Co., Ltd., and speaker’s fee from Abbvie Japan Co., Ltd., Bristol Myers Squibb K.K., Janssen. Pharmaceutical K.K., and Chugai Pharmaceutical Co. Dr. Makino is a consultant for AbbVie and Teijin, receives speaker honoraria from Boehringer-Ingelheim. Dr. Harigai has received research grants and/or honoraria from Abbott Japan Co., Ltd.; Astellas Pharma Inc.; Bristol-Myers Squibb K.K.; Chugai Pharmaceutical Co., Ltd.; Eisai Co., Ltd.; Janssen Pharmaceutical K.K.; Mitsubishi Tanabe Pharma Co.; Santen Pharmaceutical Co.; Ltd.; Takeda Pharmaceutical Co., Ltd.; Teijin Pharma, Ltd.; and Pfizer Japan Inc. Dr. Tsuchiya has received a research grant from Bristol-Myers Squibb, 2015 Japan College of Rheumatology Award from Japan College of Rheumatology and 2017 Novartis Rheumatology Award from Japan Rheumatism Association with research funding, and speaker’s honoraria from Ayumi Pharmaceutical Corporation.
Funding Information:
This study was supported by the grants from the Japan Agency for Medical Research and Development “The Study Group for Strategic Exploration of Drug Seeds for ANCA Associated Vasculitis and Construction of Clinical Evidence [grant number 17ek0109104h0003]”, “The Strategic Study Group to Establish the Evidence for Intractable Vasculitis Guideline [grant number 17ek0109121h0003]”, and “Multitiered study to address clinical questions for management of intractable vasculitides [grant number 18ek0109360h001]), and the grants awarded to NT from the Japan College of Rheumatology and the Japan Rheumatism Foundation.
Publisher Copyright:
© 2019, The Author(s).
PY - 2019/12/1
Y1 - 2019/12/1
N2 - Genome-wide association studies of systemic lupus erythematosus (SLE) in Chinese and Korean populations demonstrated strong association of single nucleotide polymorphisms (SNPs) located in the GTF2I-NCF1 region, rs73366469 (GTF2I), rs117026326 (GTF2I), rs80346167(GTF2IRD1) and rs201802880 (NCF1). This region has also been associated with susceptibility to Sjögren syndrome and rheumatoid arthritis; however, association studies with systemic sclerosis (SSc) and ANCA-associated vasculitis (AAV) have not been reported. Here we made an attempt to confirm their associations with SLE in the Japanese population, to find the primarily associated SNP, and to investigate whether these SNPs are also associated with susceptibility to SSc and AAV. By genotyping these four SNPs on 842 SLE, 467 SSc, 477 AAV patients and 934 healthy controls, striking association was confirmed in Japanese SLE. In addition, these SNPs were significantly associated with susceptibility to SSc, but not with AAV. Conditional logistic regression analysis revealed that the association of NCF1 rs201802880, a missense SNP encoding p.Arg90His, can account for the association of other SNPs by linkage disequilibrium. These results suggested that GTF2I-NCF1 region is associated with susceptibility to multiple autoimmune rheumatic diseases but not with AAV, and the primarily associated variant may be the missense SNP in NCF1.
AB - Genome-wide association studies of systemic lupus erythematosus (SLE) in Chinese and Korean populations demonstrated strong association of single nucleotide polymorphisms (SNPs) located in the GTF2I-NCF1 region, rs73366469 (GTF2I), rs117026326 (GTF2I), rs80346167(GTF2IRD1) and rs201802880 (NCF1). This region has also been associated with susceptibility to Sjögren syndrome and rheumatoid arthritis; however, association studies with systemic sclerosis (SSc) and ANCA-associated vasculitis (AAV) have not been reported. Here we made an attempt to confirm their associations with SLE in the Japanese population, to find the primarily associated SNP, and to investigate whether these SNPs are also associated with susceptibility to SSc and AAV. By genotyping these four SNPs on 842 SLE, 467 SSc, 477 AAV patients and 934 healthy controls, striking association was confirmed in Japanese SLE. In addition, these SNPs were significantly associated with susceptibility to SSc, but not with AAV. Conditional logistic regression analysis revealed that the association of NCF1 rs201802880, a missense SNP encoding p.Arg90His, can account for the association of other SNPs by linkage disequilibrium. These results suggested that GTF2I-NCF1 region is associated with susceptibility to multiple autoimmune rheumatic diseases but not with AAV, and the primarily associated variant may be the missense SNP in NCF1.
UR - http://www.scopus.com/inward/record.url?scp=85074683300&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074683300&partnerID=8YFLogxK
U2 - 10.1038/s41598-019-52920-0
DO - 10.1038/s41598-019-52920-0
M3 - Article
C2 - 31705128
AN - SCOPUS:85074683300
SN - 2045-2322
VL - 9
JO - Scientific Reports
JF - Scientific Reports
IS - 1
M1 - 16366
ER -